Stanley Hirsch

Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel

Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel

Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel

Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel

Rimonyx Pharmaceuticals Ltd. develops drugs targeted at glycosaminoglycan and protein interactions. It identified a series of novel anti-inflammatory compounds and has recently partnered its lead drug candidate, RX-111, for further preclinical and clinical development. It is focused on developing additional products for a variety of inflammatory and autoimmune indications. The company was founded in 2001 and is headquartered in Ness-Ziona, Israel